KDM1A and prostate carcinoma: N-ethyl-2,4-dihydroxy-5-isopropyl-N-(3-((methyl (prop-2-yn-1-yl) amino) methyl) phenyl) benzamide (compound 6) is a dual LSD1 and heat shock protein 90 (HSP90) inhibitor, effectively affecting the survival of prostate cancer cells and patient-derived colorectal cancer organoids [231].